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The Superﬁcial
Femoral Artery Conundrum
So Close, Yet So Far Away!*
Thomas T. Tsai, MD, MSCyzx
Denver, Colorado
The endovascular treatment of the superﬁcial femoral artery
(SFA) remains one of the biggest conundrums for inter-
ventionalists in everyday clinical practice. Whereas we have
grown accustomed to excellent endovascular outcomes in the
coronary, carotid, renal, and iliac arteries, the femo-
ropopliteal (FP) artery continues to be our “Achilles heel,”
exhibiting relatively poor primary patency rates, from 77% to
86.1% at 1 year in prospective clinical trials, with much
poorer rates in the real world (1,2). Many reasons have been
implicated, including the SFA’s location deep in the thigh,
which undergoes constant conformational changes (e.g.,
extension/contraction, torsion, compression, and ﬂexion),
its unique anatomic complexities (e.g., increased incidence
of chronic total occlusions [CTO], diffuse disease, and
dense calciﬁcations), and common ﬂow perturbations both
upstream and downstream (e.g., inﬂow disease and poor
tibial runoff). Although the effectiveness (patency) of these
procedures continues to be a challenge, the safety is superb,
with a 30-day freedom from composite death, target limb
amputation, and reintervention of >99% and same-day
discharge for most patients (3,4). As in other arterial beds,
this safety advantage of endovascular procedures over open
surgery has led to a shift toward a less invasive approach to
treating symptomatic SFA disease, with an increase in the
use of peripheral vascular intervention procedures by more
than 1,000% in the last 2 decades (5,6).See page 792With this explosion of endovascular procedures, con-
sensus recommendations have developed around the anat-
omic distribution, number, and nature of lesions (stenosis,
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contents of this paper to disclose.decisions (7,8). The revised Trans-Atlantic Inter-Society
Consensus Classiﬁcation (TASC) II document recom-
mends endovascular therapy for type A and B lesions, and
recommends surgery for type D lesions. Patients with type C
lesions who are not good risk candidates for surgery may also
beneﬁt from an endovascular approach. Since 2000, the
classiﬁcation schemes in the femoropopliteal (FP) region
have been modiﬁed to reﬂect the technological advances in
endovascular equipment such that type D lesions only
include CTO of the SFA >20 cm, involving the popliteal
artery, or CTO of the popliteal artery including the proximal
trifurcation vessels (8).
In this issue of JACC: Interventions, Iida et al. (9) studied
2,400 limbs from 1,889 consecutive patients who underwent
successful endovascular therapy (EVT) for de novo FP
lesions. This study was a subanalysis of the REAL-FP
(Retrospective Multicenter Analysis for Femoropopliteal
Stenting) registry, a nonrandomized multicenter registry
representing 13 institutions in Japan. Using this retrospec-
tive registry, the investigators contributed 3 main ﬁndings to
the existing literature.
1. In a large cohort using relatively contemporary
techniques and devices, primary patency was 80% in
the TASC II A to C group versus 69% in the TASC II
D group at 1 year, 62% versus 48% at 3 years, and 49%
versus 34% at 5 years, consistently demonstrating
reasonable rates of primary patency in the TASC II A
to C group up to 5 years.
2. Common restenosis determinants for TASC II A
to C and D lesions included: 1) diabetes mellitus; 2) no
stent usage; 3)CTO; and4) poor below-the-knee runoff.
3. There may be a differential effect of the variables
female sex and renal insufﬁciency on restenosis in
TASC II A to C versus D lesions.
Beyond the speciﬁc ﬁndings, the study by Iida et al. (9)
represents a growing trend of research in peripheral arterial
disease to capture procedural and patient-level data, either
retrospectively or prospectively. In this case, a large retro-
spective registry of 13 institutions in Japan compiled their
data to focus on FP stenting in 3,471 limbs in 2,759
consecutive patients. Because of the large cohort size and
number of follow-up events, multivariable modeling deter-
mined that diabetes, no stent use, CTO, and below-
the-knee runoff were shared risk predictors for restenosis
consistent between TASC II A to C and D lesions.
Furthermore, interaction terms can be added to the models
to ascertain whether certain variables have a differential
impact on different strata. In this study, chronic kidney
disease and female sex predicted restenosis in only the
TASC II A to C and D lesions, respectively. Concretely,
these data reiterate what can be expected when FP lesions
are treated with EVT and reconﬁrm which variables are
associated with the loss of primary patency.
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800Although this study and studies like these (single-
arm observational studies) continue to provide data on the
technical outcomes of one end of the spectrum of treatment
(EVT), true comparative effectiveness studies focused on the
merits of one treatment versus another are lacking, and
limited attention is being paid to patient-centered health
status measures and patient preference, which are the cor-
nerstones of treatment selection. Moving forward, there is a
strong need to refocus our agenda in peripheral artery disease
(PAD) research to best serve our patients. Comparative
effectiveness research deﬁned by the Institute of Medicine as
“the generation and synthesis of evidence that compares the
beneﬁts and harms of alternative methods to prevent,
diagnose, treat, and monitor a clinical condition or to
improve the delivery of care” is in its infancy in PAD
research (10). Prospective registries need to incorporate the
clinical spectrum of PAD treatment to include exercise
programs, pharmacological therapies, EVT, and open sur-
gery with consistent deﬁnitions and outcome metrics to
compare the safety and effectiveness of different treatment
options. The Institute of Medicine also envisioned a more
patient-centered healthcare system focused on patients’
functional status and health-related quality of life (deﬁned as
the patient’s perceived physical, emotional, and social well-
being and function). Treatment of claudication is entirely
focused on improving health status rather than survival or
limb preservation. How should we weigh the tradeoffs of
repeat revascularization with EVT compared with the
increased periprocedural complications and recovery time of
open surgical bypass? How shall we counsel patients with
regard to exercise programs, pharmacological therapy, and
invasive treatment? What bearing does primary and sec-
ondary patency have on a patient’s functional status and
quality of life? Disease-speciﬁc questionnaires like the
Peripheral Artery Questionnaire and the Walking Impair-
ment Questionnaire are just a few of the validated tools in
assessing functional status and quality of life in patients with
lower extremity claudication (11). Large national prospective
registries like the recently launched NCDR (National
Cardiovascular Data Registry), the PVI (Peripheral Vascular
Intervention) registry, and the Society for Vascular Surgery’s
VQI (Vascular Quality Initiative) registry need to incorpo-
rate functional assessment and quality-of-life measures to
their efforts to allow meaningful comparisons of different
treatment beyond technical success and periprocedural
complications. Lastly, the PAD community must encourage
our industry partners, funding agencies, and academic af-
ﬁliates to design meaningful randomized controlled trials
comparing emerging technologies such as drug-eluting
balloons to bare-metal self-expanding stents as opposed to
balloon angioplasty with provisional stenting. The current
focus of most trials is for device approval as opposed todevice superiority, which has led to the concept of the “Wild
Wild West” in EVT. Unless we address the gaps in our
research portfolio in the care of patients with claudication,
we will continue to be close, yet so far away.
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